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Bcl-2 is an intracytoplasmic and membrane-associated apoptosis suppressor, and its overexpression is closely associated with
survival of malignant tumors, in particular their aggressive behavior and poor prognosis. The role of Bcl-2 is, however, still
controversial in cholangiocarcinogenesis because of the discrepancies in the expression of the protein. In the present study,
alteration in the expression of Bcl-2 in cholangiocarcinogenesis was investigated by studying the immunoreactivities of this
protein in normal, hyperplastic bile ducts with or without dysplastic changes, and neoplastic bile duct cells from a hamster
cholangiocarcinoma (ChC) model. Cytoplasmic staining, which reﬂects high-Bcl-2 immunoreactivity, was negative to very
weak in normal and hyperplastic bile ducts without dysplastic changes, while hyperplastic bile ducts with dysplasia indicated
heterogeneously strong expression. On the other hand, most of the neoplastic cells of invasive cholangiocarcinomas were negative
to weak as much as the level of normal bile ducts. The results suggest that the antiapoptotic factor Bcl-2 plays a limited role in
the survival of highly proliferative, potentially dysplastic bile duct cells. However, the role of Bcl-2 in biliary cancer cells was not
signiﬁcant.
1.Introduction
Apoptosis, the so-called programmed cell death or cell sui-
cide,isakeyregulatorymechanisminthediﬀerentiationand
maturation of an organism and during the development of
cancer. Apoptosis is also essential for removing irreparable,
damaged, and transformed cells in adults [1, 2]. Apoptosis is
regulated by a variety of genes, including Bcl-2 and p53. p53
induces apoptosis to protect the body against cells that be-
have in a discoordinated fashion or have damaged DNA. The
Bcl-2 oncogene inhibits apoptosis as a generalized cell death
suppressor, thus allowing the accumulation and propagation
of cells containing genetic alterations [3]. Altered expression
of cell-survival genes such as Bcl-2 induces a malfunction in
the apoptosis-regulating machinery and is therefore closely
associated with carcinogenesis [4, 5]. Earlier studies reported
aberrant Bcl-2 expression in a variety of tumors, such as ade-
nocarcinoma of the prostate, bladder carcinoma, squamous
cell carcinoma of the lung, nasopharyngeal carcinoma, and
breast carcinoma [6–11].
Cholangiocarcinoma (ChC) is a highly malignant, gen-
erally fatal adenocarcinoma arising from bile-duct epithelial
cells of the intrahepatic or extrahepatic biliary system.
Although it is a relatively rare tumor, the incidence of ChC is
increasing globally [12]. Despite advances in ChC diagnosis,
surgery oﬀers the only possibility of relatively long-term sur-
vival[13].Nevertheless,the5-yearsurvivalrateaftercurative
resection is less than 30% [14]. The pathogenesis of biliary
cancer remains unknown, but oxidative damage, oncogene
activation, and impaired apoptosis may be involved [15].
In association with antiapoptosis, Bcl-2 overexpression has
been implicated in carcinogenesis. However, data regarding
Bcl-2 expression in human ChC are controversial, and the
antiapoptotic mechanism in ChC cells remains unknown
[8, 16–19]. Some studies have indicated that ChC expresses
Bcl-2. Studies involving several hematological and solid2 The Scientiﬁc World Journal
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Figure 1: The time points of liver specimen collections in the hamster cholangiocarcinoma model. The liver specimens were respectively
prepared at the precancerous phase (8 weeks after ChC model initiation) and the cancerous phase (27 weeks after the model initiation)
as well as from the negative control hamsters. The hamster ChC model was composed of the initiation process by the treatment of
dimethylnitrosamine (DMN) and infestation of 15 Clonorchis sinensis metacercariae as a strong promoter.
malignancies have identiﬁed a correlation between intense
Bcl-2 or Bcl-XL expression and poor patient response to
cancer therapy and overall prognosis. A study by Charlotte
et al. [8] reported that eight of 11 cases expressed Bcl-2
and suggested that the Bcl-2 protein could be a unique ChC
marker. A study by Terada and Nakanuma [20] found Bcl-2
expressioninoneof20ChCsandsuggestedthataroleofBcl-
2 is limited in ChC. These results correspond to the ﬁndings
in experimental models.
We investigated altered Bcl-2 protein expression patterns
during hamster cholangiocarcinogenesis to evaluate the role
of Bcl-2 using immunohistochemical analyses.
2.MaterialsandMethods
2.1. Tissue Samples. Five paraﬃn-embedded tissue blocks of
hamster livers with precancerous biliary lesions and ChC, as
well as normal hamster livers, were prepared from hamster
ChC models. The precancerous lesions were obtained from
hamsters 8 weeks after inducing the hamster ChC model
(interim phase of cholangiocarcinogenesis), and ChC tissues
were obtained with tumor masses at 27 weeks (Figure 1). As
described in a previous study, precancerous hamster livers
were characterized by hyperplastic bile ducts with or without
cellulardysplasiaandintensesurroundinginﬂammation;the
ChCs were invasive tubular or tubulopapillary-type primary
biliary cancers [21].
2.2.Bcl-2Immunohistochemistry. Theavidin-biotin complex
method was used for Bcl-2 immunohistochemistry. After
dewaxing with xylene and rehydration through a graded
ethanol series, tissue sections were immersed in methanol
(Daejung Chemicals and Metals, Siheung City, republic of
Korea) containing 0.3% hydrogen peroxide (Showa Chem-
icals, Tokyo, Japan) for 30min at room temperature to
block endogenous peroxidase activity. Microwave antigen
retrieval was performed using a preheated target-retrieval
solution (0.01M, pH 6.0; DakoCytomation, Carpinteria,
CA, USA) followed by a 15min incubation. This was
f o l l o w e db yt r e a t m e n tw i t had e t e r g e n t ,w h i c hc o n s i s t e d
of soaking the samples in phosphate-buﬀered saline (PBS)
containing 0.05% Tween 20 (pH 7.2). After three 5min
washes in PBS, the tissue sections were incubated with
normal blocking serum and prepared according to the
manufacturer’s instructions supplied in the Vectastain Elite
ABC Kit (Vector Labs, Burlingame, CA, USA) for 1h at
room temperature. Avidin D and biotin blocking reagents
(Vector Labs) were added to the sections according to the
manufacturer’s instructions to minimize background stain-
ing due to endogenous biotin or biotin-binding proteins,
lectins, or nonspeciﬁc binding substances present within
the tissue sections. The sections were then incubated with
dilutedprimaryantibody(rabbitpolyclonalanti-humanBcl-
2 IgG 1:50, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) overnight at 4◦C. As a negative control, PBS was used
instead of the primary antibody. Thereafter, the sections
were washed with PBS and incubated with the appropriate
biotinylated secondary antibody according to the Vectastain
E l i t eA B CK i tf o r4 0m i na tr o o mt e m p e r a t u r e ,f o l l o w e db ya
30min incubation with ABC reagent at room temperature.
The sections were visualized with 3,3-diaminobenzidine
tetrahydrochloride solution (DakoCytomation) containing
3% hydrogen peroxide and counterstained with Mayer’s
hematoxylin (Sigma-Aldrich, St. Louis, MO, USA). This
was followed by routine dehydration in alcohol, clearing in
xylene, and mounting.
2.3. Semiquantitative Evaluation of Bcl-2 Immunoreactivity.
We counted the hyperplastic and dysplastic bile ducts in six
h a m s t e rl i v e r sa t8w e e k sa n di n1 0h a m s t e rl i v e r sa t2 7w e e k s
to semiquantitatively evaluate Bcl-2 immunoreactivity in
the biliary cell populations during cholangiocarcinogenesis.
Sections were evaluated at high-power magniﬁcation from a
series of 10 randomly selected adjacent ﬁelds under a light
microscope ﬁtted with an ocular grid. In total, 100, 811,
and 4890 biliary epithelial cells were counted in the hamster
livers at normal, precancerous, and carcinogenic phases,
respectively. Bcl-2 immunoreactivity in the biliary cell pop-
ulations, including biliary cancer cells, was represented as
the percentage of negative, weak (1+), moderate (2+), or
strongly (3+) positive bile ducts or neoplastic cells for Bcl-2
to the total number of bile ducts or neoplastic cell numbers.
Basedonthecriteria,alightmicroscopicexamination ofBcl-
2immunoreactivitywasperformedblindlybytwoveterinaryThe Scientiﬁc World Journal 3
pathologists. Statistically signiﬁcant diﬀerences between the
biliary cell populations were detected using Student’s t-test.
Statistical signiﬁcance was determined at P<0.05.
2.4. Western Blot Assay. As the Bcl-2 antibody used for im-
munohistochemistryoriginatedfromhumanBcl-2,thereac-
tivityandspeciﬁcityoftheprimaryantibody againsthamster
Bcl-2 were tested by western blot assay. Additionally, Bcl-
2 protein levels were respectively evaluated in precancerous
hamster livers, the biliary tumor mass, and in normal livers.
Protein was extracted from the all liver tissues according
to a previous study [21]. Brieﬂy, the frozen hamster liver
tissues were ﬁnely ground and dissolved by repeatedly
passing them through a 26-gauge needle attached to a
syringe containing protein extraction buﬀer (Intron, Chinju,
Republic of Korea). After a 15min incubation at 20◦C, the
suspension was centrifuged at 13,000rpm for 5min at 4◦C.
The protein extracts (20µg) were subjected to 12% (w/v)
SDS-polyacrylamide gel electrophoresis and transferred to
PVDF membranes (Bio-Rad Lab., Hercules, CA, USA). After
blocking the nonspeciﬁc binding sites by incubating the
membranes with 5% nonfat dried milk and 0.1% Tween 20
in Tris-buﬀered saline (pH 7.4) for 1h at room temperature,
themembraneswereincubatedovernightat4◦Cwithdiluted
primary antihuman Bcl-2 antibody at a 1:200 dilution,
followed by an incubation with secondary antibody for
50min at room temperature. To visualize the bands, the
membranes were treated with a detection reagent for 1min,
exposed to ﬁlm, and then developed using a SEER medical
ﬁlm processor (SEER Technologies Inc., Seoul, Republic of
Korea).
3. Results
High Bcl-2 expression was limited in some hyperplastic bile
ducts with dysplastic changes during hamster cholangiocar-
cinogenesis. Most of the hyperplastic bile ducts were almost
negative to weakly positive (Figure 2), and only 2.7% of
the counted hyperplastic bile ducts showed high expression
graded as >2+ (Figure 3). The hyperplastic bile ducts strong-
ly expressing Bcl-2 were those with dysplastic changes,
whereas the hyperplastic bile ducts without morphological
transformation were all negative or very weakly positive
(Figure 2). Hepatocytes in the precancerous hamster livers
were generally negative. Sinusoidal, lymphocytes, eosino-
phils, macrophages, and plasma cells often showed strong
Bcl-2 immunoreactivity.
The percentage of biliary cancer cells showing high Bcl-
2 expression (above grade 2+) was much lower; it was less
than 1% of the counted cancer cells in all of the ChCs
examined (Figure 3). Hepatocytes in the cancerous phase
did not express Bcl-2. In the normal hamster liver, all
liver parenchymal cells including biliary epithelial cells and
hepatocytes were negative for Bcl-2 (Figure 2).
WevalidatedthespeciﬁcityoftheBcl-2antibodyusedfor
immunohistochemistry using a western blot assay because
the antibody originated from human Bcl-2. As shown in
Figure 4, clear bands were noted at 21kD, corresponding to
that of the Bcl-2 protein. The protein was prepared from
the whole liver tissue which includes not only bile duct
cells but also hepatocytes and other liver cell components.
Thus, the results of western blotting could not absolutely
reﬂect the expression of Bcl-2 in bile duct cells, but no
notable changes in expression were found in precancerous
liver tissues or in the ChC samples. Rather the expression
of Bcl-2 was likely reduced in the ChC tissues, compared to
normaltissues,whichwasasimilarexpressionpatterntothat
of immunohistochemistry.
4. Discussion
Bcl-2 is a well-known general apoptosis suppressor that
induces the formation and development of carcinomas and
suppresses apoptosis. Bcl-2 is a critical factor in carcino-
genesis [1], and Bcl-2 overexpression has been implicated
in various tumors [6, 7, 9, 10, 19, 22]. However, Bcl-2
expression is controversial in normal liver cell components
as well as in biliary cancers [8, 19]. A study by Charlotte et
al. [8] reported the expression of the protein in epithelial
cells of the intrahepatic small ducts, but not in hepatocytes
or large bile duct cells, whereas a study by Okaro et al. [19]
found no positive immunoreactivity in any of the biliary
cell populations. Similarly, conﬂicting results have also been
reported for Bcl-2 expression in association with ChC. Bcl-2
immunoreactivity occurred in more than 80% of the human
ChC cases examined by Charlotte et al. [8], whereas no
positive signal was found by Okaro et al. [19].
In the present study, the immunohistochemical Bcl-2
expressionpatternswerecomparedinsamplesobtainedfrom
hamster livers at serial cellular stages of cholangiocarcino-
genesis as well as from normal livers. The results indicated
heterogeneously strong expression of Bcl-2 in dysplastic bile
ducts but negative to weak immunoreactivity in normal and
hyperplastic small bile ducts. Despite such heterogeneous
Bcl-2 expression in the biliary cell populations, overexpres-
sion of the protein in a limited number of dysplastic bile
ducts suggests that it plays a role in ChC through survival
of the transformed bile duct cells, which are presumably
candidates for developing ChC. A high concentration of the
antiapoptotic protein Bcl-2 within the biliary tree might
allow cells that harbor growth promoting mutations, such as
K-ras, c-erb-B-2, or c-myc mutations, to survive by evading
apoptosis [15]. Furthermore, these expression patterns may
explain the controversial Bcl-2 data generated by previous
studies. Most studies investigating Bcl-2 expression in ChCs
have reported varying degrees of Bcl-2 protein expression
[8, 16, 18, 23, 24]. A study by Charlotte et al. [8] showed that
the Bcl-2 protein is expressed by small bile duct epithelia in
normalliversbutnotbyhepatocytesorcellsofthelargeduct.
These authors suggested that the Bcl-2 protein is a diagnostic
marker to distinguish ChC from hepatocellular carcinoma.
A study by Skopelitou et al. [16] found Bcl-2 expression in
normal small bile duct epithelia and in all cases of ChC,
whereas it was not detected in neoplastic and dysplastic bile
ducts, or normal hepatocytes. A study by Skopelitou et al.
[16] also suggested that Bcl-2 appears to be a marker that
distinguishes hepatocellular carcinoma from ChC. However,
Bcl-2 expression in ChCs is also very controversial. A study4 The Scientiﬁc World Journal
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Figure 2: Immunohistochemistry for Bcl-2 in the liver tissue sections taken from cholangiocarcinoma (ChC) model and control group
animals. (a) and (b) Normal bile ducts; (c) and (d) hyperplastic bile ducts; (e) and (f) dysplastic bile ducts; (g) and (h) cholangiocarcinoma.
Bcl-2 staining was negative or weakly positive in normal and hyperplastic bile duct cells. Characteristically, Bcl-2 was heterogeneously
expressed in the tissues (arrow in (d)). The Bcl-2 protein was strongly expressed in the cytoplasm of dysplastic biliary cells, although Bcl-2
expression was heterogeneous (arrow in (f)). Bcl-2 expression was negative or very weak in ChCs, similar to control levels (arrow in (h)).
(a), (c), (e), and (g) hematoxylin and eosin stain; (b), (d), (f), and (h) Bcl-2 immunohistochemistry; (a)–(d) bars = 22.5µm; (e)–(h) bars =
45µm.
by Guo et al. [23] reported that 21 of 29 ChCs express the
Bcl-2 protein (72.4%). In contrast, a study by Ito et al. [18]
reported that only 31.7% (13/41) of ChCs are positive for
Bcl-2 and that Bcl-2 expression was found in only 23.6%
of ChCs and exhibited a strong association with tumor
localization. Furthermore, some studies have reported that
none of the ChC samples express Bcl-2 protein [17, 19, 20].
A study by Arora et al. [17] reported that most ChC cases
did not express immunohistochemically detectable amounts
of Bcl-2 protein and that its function could be performed
by other proteins such as Bcl-XL.As t u d yb yT e r a d aa n d
Nakanuma [20] also showed low or negative expression
of Bcl-2 in bile duct epithelia and ChCs. In our paper,
only 14.1% (690/4875) of small bile duct epithelia at theThe Scientiﬁc World Journal 5
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Figure 3: Semiquantitative analysis of Bcl-2 immunoreactivity
in biliary cell populations at the precancerous and carcinogenic
phases of cholangiocarcinogenesis in hamsters. The percentage
of normal biliary cell populations with diﬀerent grades of Bcl-
2 immunoreactivity during cholangiocarcinogenesis in hamsters.
The numbers on the columns represent the percentages of Bcl-2-
positive cells. In total, 100, 811, and 4890 bile ducts were counted
in the hamster livers at the normal, precancerous, and carcinogenic
phases, respectively. Strong Bcl-2 immunoreactivity was found
in some hyperplastic bile ducts with dysplastic changes at the
precancerous phase. However, only <1.0% of neoplastic cells of
cholangiocarcinomasindicatednotableexpressionofBcl-2.Normal
andhyperplasticbileductswithoutdysplasticchangeswerenegative
to very weak positive for Bcl-2.
Bcl-2
Normal
Precancerous
phase
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phase
β-actin
Figure 4: Western blot analysis for Bcl-2 in normal, precancerous,
andneoplasticlivertissuesinahamstercholangiocarcinomamodel.
Note the speciﬁc bands made by the same antibody used for
immunohistochemistry. No notable changes in the expression of
Bcl-2 protein were found in the precancerous and cancerous liver
tissues. The Bcl-2 expression was, compared to that of normal liver,
more likely reduced in ChC tissues, which was in accordance with
the results of immunohistochemistry.
carcinogenicphasewerepositiveforBcl-2,indicatingthatthe
role of Bcl-2 in ChCs is not very signiﬁcant.
We were interested in determining what other molecules
could play an important role in cancer cell survival and that
are essential for tumor growth. Thus, we focused on the
expression pattern of thioredoxin (Trx), a redox component
and another apoptosis-inhibiting factor, during various sta-
ges of hamster and human cholangiocarcinogenesis [21]. Trx
was heterogeneously expressed in hyperplastic bile ducts
with morphological alterations, which wassimilar to the Bcl-
2 expression pattern. However, unlike Bcl-2, high Trx expres-
sion continued consistently into the carcinogenic phase; Trx
was overexpressed in hamster and human ChCs. We were
unable to determine if an interacting relationship occurred
between Bcl-2 and Trx during cholangiocarcinogenesis, but
compensatory relationships between these two proteins were
recentlyreportedbyLietal.[25].Accordingtothatstudy,Trx
is correspondingly upregulated with Bcl-2 downregulation,
following transfection of neuroblastoma cells with antisense
Bcl-2. Further studies are needed to verify whether a similar
relationship between Trx and Bcl-2 is involved in cholangio-
carcinogenesis.
Why such a discrepancy in Bcl-2 expression is present
in human ChCs as well as normal bile ducts in previous
studies is still unclear but may have arisen because of the
diﬀerent methods used or diﬀerences in the ChC specimens.
In our study, the same procedures were applied to all speci-
mens, including ﬁxation, tissue processing, and immunohis-
tochemistry. The speciﬁcity of the Bcl-2 antibody used in the
hamster livers was also validated by western blotting.
In summary, Bcl-2 was heterogeneously overexpressed in
a limited number of dysplastic bile duct epithelial cells in a
hamster ChC model, suggesting that the protein plays some
role in cell survival of transformed bile duct cells. However,
its role in the carcinogenic phase of ChCs was not signiﬁcant
in the present hamster ChC model.
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